Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.

Anywaine Z, Barry H, Anzala O, Mutua G, Sirima SB, Eholie S, Kibuuka H, Bétard C, Richert L, Lacabaratz C, McElrath MJ, De Rosa SC, Cohen KW, Shukarev G, Katwere M, Robinson C, Gaddah A, Heerwegh D, Bockstal V, Luhn K, Leyssen M, Thiébaut R, Douoguih M, EBL2002 Study group

Open source

DOI: 10.1371/journal.pmed.1003865
Published: 2022 Jan
Container: PLoS medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1371/journal.pmed.1003865,
  title = {Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.},
  author = {Anywaine Z and Barry H and Anzala O and Mutua G and Sirima SB and Eholie S and Kibuuka H and Bétard C and Richert L and Lacabaratz C and McElrath MJ and De Rosa SC and Cohen KW and Shukarev G and Katwere M and Robinson C and Gaddah A and Heerwegh D and Bockstal V and Luhn K and Leyssen M and Thiébaut R and Douoguih M and EBL2002 Study group},
  year = {2022},
  journal = {PLoS medicine},
  doi = {10.1371/journal.pmed.1003865},
  url = {https://doi.org/10.1371/journal.pmed.1003865}
}

RIS

TY  - JOUR
TI  - Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
AU  - Anywaine Z
AU  - Barry H
AU  - Anzala O
AU  - Mutua G
AU  - Sirima SB
AU  - Eholie S
AU  - Kibuuka H
AU  - Bétard C
AU  - Richert L
AU  - Lacabaratz C
AU  - McElrath MJ
AU  - De Rosa SC
AU  - Cohen KW
AU  - Shukarev G
AU  - Katwere M
AU  - Robinson C
AU  - Gaddah A
AU  - Heerwegh D
AU  - Bockstal V
AU  - Luhn K
AU  - Leyssen M
AU  - Thiébaut R
AU  - Douoguih M
AU  - EBL2002 Study group
PY  - 2022
JO  - PLoS medicine
DO  - 10.1371/journal.pmed.1003865
UR  - https://doi.org/10.1371/journal.pmed.1003865
ER  -

APA

Z, A., H, B., O, A., G, M., SB, S., S, E., H, K., C, B., L, R., C, L., MJ, M., SC, D. R., KW, C., G, S., M, K., C, R., A, G., D, H., V, B., K, L., M, L., R, T., M, D., & group, E. S. (2022). Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.. PLoS medicine. https://doi.org/10.1371/journal.pmed.1003865

Source records

pubmed · retrieved 2026-09-25T12:12:27.502Z